Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
A phase 2 trial of BCB-276 in diffuse midline glioma, h3 k27-altered, run by BrainChild Bio, Inc, now recruiting.
Overview
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). is a phase 2 interventional study registered as NCT07680439 by BrainChild Bio, Inc, with 75 participants planned, started 2026-08 and due to reach its primary completion in 2028-10. Interventions recorded: BCB-276. Conditions listed: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor. No results are recorded here; the registry entry is the source.
Setting
A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma
Phase
Phase 2
Sponsor
BrainChild Bio, Inc
Registry
Enrolled
75